Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab - Fierce Pharma

Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab    Fierce Pharma WHO and Gilead Sciences renew partnership to accelerate visceral leishmaniasis elimination    World Health Organization (WHO) Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi    Pharmaceutical Executive Gilead Renews WHO Partnership to Fight Deadly Kala-Azar    Contract Pharma Gilead teams up with WHO again to eliminate parasitic tropical disease    Yahoo

Original source: Google News